Sistemic announces companion biomarker programme

Published: 4-Jul-2011
Research & Development

Extends miRNA drug discovery toolkit

Sistemic, a global company with expertise in microRNA, has released a new companion biomarker programme, which extends its SistemRNA suite of drug discovery and development tools.

The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

See more

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Read more
Cell therapy companies to be offered a streamlined process for clinical trials

Trending Articles

  1. Prellis biologics partners with Eli Lilly to advance next-generation human antibody therapeutics Prellis will combine its EXIS organoid and AntiGen AI platforms with Lilly’s research and development expertise, aiming to accelerate the discovery of fully human antibodies for multiple disease targets
  2. Concept Life Sciences opens expanded drug discovery facilities in Chapel-en-le-Frith The expansion makes the facility one of the UK’s largest integrated drug discovery sites, bringing chemistry, ADMET and screening biology under one roof
  3. CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction at 24 weeks
  4. SynGenSys introduces NK.SET synthetic promoter library to advance natural killer cell therapies First commercially available NK (natural killer) cell-specific promoter library enables precise and controllable gene expression
  5. Abzena Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK).

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Regulatory

Scotland launches collaborative approach to cell therapy development

Cell therapy companies to be offered a streamlined process for clinical trials
Research & Development

Sistemic cuts cost of drug discovery

Launches microRNA technology to filter out harmful compounds early in development process
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Regulatory

AbbVie submits new drug application to FDA for tavapadon in Parkinson’s disease treatment

The once-daily oral dopamine D1/D5 receptor partial agonist has been supported by positive Phase III TEMPO trial results that show symptomatic improvement across the Parkinson’s disease spectrum
Subscribe now